Phase 1/2Completed

Comparative Bioavailability of Intranasal Epinephrine

A Study to Compare the Bioavailability of Epinephrine Following a Single Nasal Dose of FMXIN002 Microspheres Powder 3.6mg, and 4mg With EpiPen 0.3mg Intramuscular Injection in Healthy Adults

Sponsor
Nasus Pharma (Industry)
Enrollment
12 enrolled
Conditions
Anaphylaxis; Anaphylactic Reaction
Interventions
A: Epinephrine injection; B: FMXIN002 3.6mg; C: FMXIN002 4.0mg
Ages
adults
Registry
NCT06205134

Full record on ClinicalTrials.gov

From the registry

A Study to Compare the Bioavailability of Epinephrine following a Single Nasal Dose of FMXIN002 Microspheres Powder 3.6 mg, and 4mg with EpiPen 0.3mg Intramuscular Injection in Healthy Adults

Primary outcomes

  • Bioavailability of Epinephrine
  • Blood pressure
  • Heart rate
  • Respiratory rate

History

  1. Last registry update

  2. Study completion

  3. Primary completion

  4. Registered

  5. Started